Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer

Siegel, 2012, Cancer treatment and survivorship statistics, 2012, CA Cancer J Clin, 62, 220, 10.3322/caac.21149

Andre, 1999, CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR, Eur J Cancer, 35, 1343, 10.1016/S0959-8049(99)00150-1

Fuchs, 2007, Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study, J Clin Oncol, 25, 4779, 10.1200/JCO.2007.11.3357

Kabbinavar, 2003, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 21, 60, 10.1200/JCO.2003.10.066

Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691

Fong, 1997, Liver resection for colorectal metastases, J Clin Oncol, 15, 938, 10.1200/JCO.1997.15.3.938

Choti, 2002, Trends in long-term survival following liver resection for hepatic colorectal metastases, Ann Surg, 235, 759, 10.1097/00000658-200206000-00002

Kopetz, 2009, Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy, J Clin Oncol, 27, 3677, 10.1200/JCO.2008.20.5278

Van Cutsem, 2009, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, 360, 1408, 10.1056/NEJMoa0805019

Douillard, 2013, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer, N Engl J Med, 369, 1023, 10.1056/NEJMoa1305275

Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766

Tie, 2011, Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation, Int J Cancer, 128, 2075, 10.1002/ijc.25555

Yokota, 2011, BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer, Br J Cancer, 104, 856, 10.1038/bjc.2011.19

Price, 2011, Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer, J Clin Oncol, 29, 2675, 10.1200/JCO.2010.34.5520

Ogino, 2012, Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803, Clin Cancer Res, 18, 890, 10.1158/1078-0432.CCR-11-2246

Wan, 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell, 116, 855, 10.1016/S0092-8674(04)00215-6

Pritchard, 2007, Mouse models for BRAF-induced cancers, Biochem Soc Trans, 35, 1329, 10.1042/BST0351329

Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782

Sosman, 2012, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N Engl J Med, 366, 707, 10.1056/NEJMoa1112302

Enge, 2010

Tran, 2011, Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer, Cancer, 117, 4623, 10.1002/cncr.26086

Samowitz, 2005, Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers, Cancer Res, 65, 6063, 10.1158/0008-5472.CAN-05-0404

Tol, 2009, BRAF mutation in metastatic colorectal cancer, N Engl J Med, 361, 98, 10.1056/NEJMc0904160

Souglakos, 2009, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer, Br J Cancer, 101, 465, 10.1038/sj.bjc.6605164

Di Nicolantonio, 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer, J Clin Oncol, 26, 5705, 10.1200/JCO.2008.18.0786

Masi, 2010, Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial, Lancet Oncol, 11, 845, 10.1016/S1470-2045(10)70175-3

Richman, 2009, KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial, J Clin Oncol, 27, 5931, 10.1200/JCO.2009.22.4295

Hutchins, 2011, Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer, J Clin Oncol, 29, 1261, 10.1200/JCO.2010.30.1366

De Roock, 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol, 11, 753, 10.1016/S1470-2045(10)70130-3

Smalley, 2009, CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations, Oncogene, 28, 85, 10.1038/onc.2008.362

Gavin, 2012, Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value, Clin Cancer Res, 18, 6531, 10.1158/1078-0432.CCR-12-0605

Phipps, 2012, BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics, Cancer Epidemiol Biomarkers Prev, 21, 1792, 10.1158/1055-9965.EPI-12-0674